Qiming Venture Partners

Qiming Venture Partners' portfolio company Reunion has reached an important regulatory milestone: its Respacio® Radiotherapy Protective Hydrogel has been officially accepted into the Special Review Pathway for Class III Innovative Medical Devices by China's Center for Medical Device Evaluation (CMDE) under the National Medical Products Administration (NMPA). Designed for use in cancer radiotherapy, the Respacio® Radiotherapy Protective Hydrogel is administered through a minimally invasive injection between the tumor and the rectum. By creating a stable separation space, it significantly reduces radiation exposure to the rectum and adjacent healthy tissues, helping to effectively prevent radiation-induced rectal injuries. #MedicalInnovation #Radiotherapy #OncologyCare #HydrogelTechnology #CancerTreatment #MinimallyInvasive #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company Clinflash Healthcare Technology has introduced a new feature to its Clinflash EDC platform, Intelligent Import Recognition, designed to significantly improve the efficiency and accuracy of LNR data entry. With this new capability, users can upload source documents such as PDFs or images. The system leverages an advanced OCR engine to extract text, table structures, and layout information, which is then converted into a standardized format. It then accurately identifies and extracts key fields, and the parsed data is seamlessly imported into the EDC system's LNR configuration module. #DigitalHealth #ClinicalTrials #EDC #OCRTechnology #HealthTech #ClinicalData #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company 52TOYS recently showcased its Chaohuohua series at the China Pavilion of Expo 2025 Osaka in Japan, as part of a special cultural event highlighting Shaanxi Province. Guided by the vision of "transcending tradition, revitalizing history, and inheriting culture," the Chaohuohua series has long-standing ties to Shaanxi. In 2018, 52TOYS collaborated with the Shaanxi History Museum to launch the second Cultural and Creative Design Competition and the third 52TOYS Prototype Design Competition. The Bronze Squad, featured at the Expo, originated from this initiative—transforming traditional bronze artifacts into imaginative figures that offer a fresh and engaging way to experience cultural heritage. #CulturalInnovation #Expo2025 #OsakaExpo #CreativeDesign #CulturalHeritage #ShaanxiCulture #DesignCompetition #ToyDesign #QimingPortfolio

Qiming Venture Partners' portfolio company Berry Genomics (SZSE:000710) supported a study led by Professor Wenpan Dong and Professor Zhixiang Zhang from Beijing Forestry University, published in the journal New Phytologist. The research leveraged PacBio sequencing as well as genome assembly and annotation provided by Berry Genomics. The study demonstrates that ancient hybridization played a crucial role in driving drought adaptation and species diversification within the genus Caragana, providing the genetic basis for rapid evolutionary radiation during historical climate aridification. These findings underscore the fundamental importance of hybridization in enabling plant lineages to successfully colonize and thrive in extreme environments. #PlantGenomics #EvolutionaryBiology #AncientHybridization #DroughtAdaptation #SpeciesDiversification #NewPhytologist #GenomicsResearch #ClimateAdaptation #PlantScience #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/dYEus-6g

At the 25th Annual Conference on Cataract and Refractive Surgery hosted by the Chinese Medical Association, Qiming Venture Partners' portfolio company Vision Pro showcased a range of innovative ophthalmic solutions. Highlights included China's first Extended Depth of Focus (EDoF) intraocular lens, a comprehensive lineup of intraocular lens products, and eye massager. Vision Pro engaged with international experts to exchange insights on the latest research in ophthalmology, share clinical experiences, and discuss future product development. During the conference, Vision Pro's subsidiary also announced a strategic partnership with Korea's SEODONG, introducing the NURIEYE eye massager to the Chinese market. The device features one-touch activation and combines heat therapy, air pressure, and vibration to enhance eye microcirculation and relieve symptoms of visual fatigue. #Ophthalmology #EDoF #IntraocularLens #CataractSurgery #MedicalInnovation #EyeCare #ClinicalDevices #NURIEYE #QimingPortfolio #QimingHealthcare

Qiming Venture Partners' portfolio company CanSino Biologics (SEHK:6185, SHSE:688185) has announced that it has obtained clinical trial approval from the National Medical Products Administration (NMPA) of China to initiate relevant clinical trials for its Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell). These trials will evaluate the vaccine's safety and immunogenicity against poliomyelitis caused by poliovirus types I, II, and III infections. The Recombinant Poliomyelitis Vaccine is innovatively developed using structure-based protein design and virus-like particle (VLP) assembly, eliminating the need for live virus in production or testing. As a result, it offers enhanced safety and immune response potential. The World Health Organization (WHO) recommends it as one of the leading strategies toward global polio eradication. #PolioVaccine #ClinicalTrials #VaccineDevelopment #StructureBasedDesign #BiotechInnovation #Immunization #GlobalHealth #PolioEradication #NextGenVaccines #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gBWMVuxg

Lockin is redefining meeting room productivity with the help of Insta360 Connect, developed by Insta360 (SHSE:688775), a Qiming Venture Partners' portfolio company. Together, they are creating a seamless and intelligent meeting experience that is clear, efficient, and effortless. With Insta360 Connect, Lockin benefits from built-in Feishu Rooms integration, enabling quick, seamless meeting access. It offers instant plug-and-play compatibility with global conferencing platforms, while 4K ultra-clear visuals and advanced AI features deliver an immersive, high-quality meeting experience. The system's integrated smart whiteboard mode removes the need for an external camera, making it easier to share in-room writing and enhancing hybrid collaboration. Its compact, all-in-one design streamlines deployment and reduces IT costs. #SmartOffice #Collaboration #Innovation #VideoConferencing #MeetingTechnology #Productivity #BusinessTechnology #QimingPortfolio #QimingTechnology

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg), developed by Qiming Venture Partners' portfolio company ArkBio, has been included in the PADO-RSV priority list. Ziresovir is the first and only RSV antiviral drug to be included in the list. This is the first time WHO has included an anti-RSV drug developed from China in the paediatric drug optimization priority list. Ziresovir is the first oral anti-RSV drug that has completed a phase 3 pivotal clinical study with positive results. The phase 3 results have been published in The New England Journal of Medicine and The Lancet Child & Adolescent Health. Ziresovir has received Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China. #RSV #PediatricHealth #DrugInnovation #GlobalHealth #ClinicalResearch #AntiviralTherapy #PharmaInnovation #WHO #BreakthroughTherapy #ChildHealth #MedicalResearch #HealthcareInnovation #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/g__4DJCQ

The first PPM (Perio-Prosthetic Maintenance) International Center in Southwest China was officially inaugurated in Kunming, Yunnan Province. This milestone marks a significant step in the nationwide expansion of the PPM health management program by Bondent Group, a Qiming Venture Partners' portfolio company. Supported by Bondent's integrated strengths in digital solutions, refined treatment technologies, and access to world-class academic resources, A JIE has become the region's first local platform to establish a PPM International Center. This initiative will further advance the clinical adoption and academic exchange of the PPM approach in Yunnan. #DentalInnovation #OralHealth #DigitalDentistry #PPM #HealthcareTechnology #MedicalInnovation #QimingPortfolio #QimingHealthcare

CSR Biotech, a Qiming Venture Partners' portfolio company, showcased its independently developed super-resolution microscopy systems at the 15th China Life Science Public Platform Management and Development Symposium. CSR Biotech highlighted its latest breakthroughs and practical applications in super-resolution imaging. Among the products on display, the HIS-SIM system impressed attendees with its exceptional performance and intelligent operation, delivering precise insights for biomedical research. The SIM-Supreme stood out for its dual-modal super-resolution capability, combining fluorescence and label-free imaging to address the challenges of complex, multi-channel dynamic cellular observation. Meanwhile, Cell Xpanse pushed the boundaries of cellular imaging with high-throughput and deep-sectioning capabilities, opening up broader application prospects and taking multi-modal fluorescence super-resolution imaging into a new dimension. #SuperResolution #Microscopy #BiomedicalResearch #Innovation #AdvancedImaging #CellImaging #TechnologyForScience #QimingPortfolio #QimingHealthcare